Patent Application
20190112656
The present invention relates to a mitochondrial biomarker reflecting senescence, and to a field that visualizes senescence and provides an index of health expectancy.
Mitochondrion is an intracellular organella in charge of aerobic metabolism of somatic cells, and produces ATP that becomes energy by hydrogen transfer system and oxidative phosphorylation. It is considered that this mitochondrial function is obstructed not only by mitochondrial diseases caused by mutation of mitochondrial DNA having a replication mechanism independent of genome but also senescence. Therefore, early diagnosis of mitochondrial dysfunction and impairment evaluation not only play an important role in the selection of therapeutic strategy for and judgment of prognosis of patients with mitochondrial diseases but also are attracting attention as a senescence marker.
MELAS is a mitochondrial disease with the highest frequency, exhibiting diverse and characteristic symptoms represented by myopathy, encephalopathy, lactic acidosis and stroke-like episode. Its life expectancy from diagnosis is 5-10 years, and it is a refractory rare disease without any medicine and applicable to insurance worldwide. It progresses with repeated stroke-like attacks, and a therapy for suppressing recurrence thereof has been desired to be provided as soon as possible. MELAS is developed by single base substitution (A3243G, T3271C, G3244A, T3258C, T3291C) in the tRNALeu(UUR) gene coding region of mitochondrial DNA. Its basic pathology has long been unknown. Ohta et al. of Nippon Medical School found a unique basic pathology that taurine modification of the first letter of anticodon, which is normally observed, is lost and translational defect is induced in MELAS mutated tRNALeu(UUR), and proposed a novel disease concept of “tRNA post-transcriptional modification abnormality disease” first in the world (non-patent document 1). The present inventors jointly studied with Ohta et al. and reported that high-dose administration of taurine improved mitochondrial dysfunction of MELAS model cells and frequent stroke-like attacks have completely been suppressed for not less than 10 years in two patients (non-patent document 2). They performed Multicenter, Open, Phase 3, Doctor-initiated clinical trial to verify the efficacy of the MELAS stroke-like attack suppressive effect of a GCP test drug taurine (Health Labour Sciences Research Grant: H24-26 refractory and the like (refractory)-general-068), and achieved complete suppression of the key evaluation item, MELAS stroke-like attack, in 60% of the patients.
A compendia relating to the role of tRNA modification in human diseases has been published (non-patent document 3), and the measurement method (non-patent document 4) and compendia relating to the lack of taurine modification of mitochondrial tRNA in human mitochondrial diseases have also been published (non-patent document 5). In addition, some patent applications directed to the diagnosis or treatment taking note of mitochondrial tRNA have been filed.
1) A method for diagnosing type 2 diabetes by chemical modification of tRNA including mitochondrial tRNA, specifically, by measuring the thiomethyl modification rate of tRNA encoding lysine, is known (patent document 1).
2) A method for improving health condition of aging animals by preventing or repairing changes in metabolism associated with aging, particularly changes leading to mitochondrial functional disorder, is known (patent document 2). Glutathione is a major intracellular antioxidant system that prevents oxidative damage of mitochondrial DNA (mtDNA). Oxidation of glutathione itself proceeds with aging and the antioxidant function decreases. It is described relating thereto that the oxidative damage of mtDNA can be prevented by supplying a thiol compound such as taurine and the like. However, the relationship between taurine modification rate of tRNALeu(UUR) and senescence is not described.
3) A therapeutic drug for a mitochondrial disease containing taurine, taurine chloramine, taurine precursor and the like as an active ingredient is known (patent document 3). However, it is not disclosed or suggested that the taurine modification rate of normal mitochondrial tRNALeu(UUR) decreases due to aging and senescence (decline of biological function) due to genetic factors, lifestyle and environmental factors and the like and that the decrease is improved by administering taurine.
A first object of the present invention is to provide a novel biomarker leading to an early detection and impairment severity evaluation of mitochondrial dysfunction associated with senescence.
A second object of the present invention is to provide an agent for improving a decrease in the taurine modification rate of mitochondrial tRNALeu(UUR), which induces decline in the mitochondrial function and is associated with senescence.
Lactate value of blood and cerebrospinal fluid, and the ratio of lactic acid value to pyruvic acid value that have been clinically used heretofore as mitochondrial disease markers rise due to conditions in which anaerobic metabolism is promoted by mitochondrial disease. They also rise due to glycolytic metabolism promoted by tissue hypoxia, that is, various pathologies such as shock, respiratory failure, disseminated intravascular coagulation syndrome and the like. Thus, these markers have low specificity (Kraut J A, Madias N E. Lactic acidosis. N Engl J Med. 2015; 372(11):1078-1079). The present inventors have measured the taurine modification rate of mitochondrial tRNALeu(UUR) of leukocyte samples of the test subjects and intensively studied usefulness of the mitochondrial disease marker. Specifically, they observed not only a decrease in the taurine modification rate of mutated mitochondrial tRNALeu(UUR) but also a decrease in the taurine modification rate of normal mitochondrial tRNALeu(UUR) in mitochondrial disease patients, and unexpectedly found that the taurine modification rate of normal mitochondrial tRNALeu(UUR) could be an index of senescence. Then they conceived the index can be applied to healthy human as well as mitochondrial disease patients, which resulted in the completion of the present invention. Furthermore, the present inventors have found that the administration of a large amount of taurine not only increases the taurine modification rate of mutated mitochondrial tRNALeu(UUR), but also increases the taurine modification rate of normal mitochondrial tRNALeu(UUR) in mitochondrial disease patients, which resulted in the completion of the present invention.
The present invention provides the following.
[1] A method for measuring senescence of a test subject, comprising a step of measuring a level of taurine modification of mitochondrial tRNALeu(UUR) in a biological sample isolated from a test subject, by a reverse transcription reaction from a primer with the tRNALeu(UUR) as a template.
[2] The method of [1], wherein the primer is an oligonucleotide 10-25 bases in length and complementary to the template, and a difference in primer elongation products is detected based on the presence or absence of taurine modification.
[3] The method of [1] or [2], wherein the primer is at least one kind comprising a base sequence selected from the group consisting of base sequences shown in SEQ ID NOs: 3, 4 and 5.
[4] The method of any of [1] to [3], further comprising a step of calculating a quantitative ratio of a primer elongation product from tRNALeu(UUR) with taurine modification and a primer elongation product from tRNALeu(UUR) without taurine modification.
[5] The method of any of [1] to [4], wherein a total taurine modification rate represented by the following formula (1):
total taurine modification rate=τm5U/(U+τm5U)×100(%) (1)
wherein τm5U is an amount of primer elongation product from tRNALeu(UUR) with taurine modification and U is an amount of a primer elongation product from tRNALeu(UUR) without taurine modification, is an index of senescence.
[6] The method of [5], wherein the test subject is suspected to have a mutated mitochondrial DNA having a single base substitution selected from the group consisting of A3243G, T3271C, G3244A, T3258C and T3291C in the tRNALeu(UUR)gene coding region, and a normal taurine modification rate determined by the following formula (2):
normal taurine modification rate=total taurine modification rate/(100-mtDNA point mutation rate)/100(%) (2)
(in the above-mentioned formula, the mtDNA point mutation rate is the highest point mutation rate selected from the group consisting of point mutations at 14-position A (A3243G), 15-position G (G3244A), 29-position T (T3258C), 42-position T (T3271C) and 62-position T (T3291C) in a DNA encoding tRNALeu(UUR) shown in SEQ ID NO: 1) successively from the aforementioned formula (1) is the index of senescence.
[7] A senescence determining drug comprising a primer comprising a base sequence consisting of 10-25 bases and complementary to the mitochondrial tRNALeu(UUR).
[8] The drug of [7], wherein the primer is at least one kind comprising a base sequence selected from the group consisting of the base sequences shown in SEQ ID NOs: 3, 4 and 5.
[9] A senescence determination kit comprising a primer comprising a base sequence consisting of 10-25 bases and complementary to the mitochondrial tRNALeu(UUR) and a reverse transcriptase.
[10] The kit of [9], wherein the primer is at least one kind comprising a base sequence selected from the group consisting of the base sequences shown in SEQ ID NOs: 3, 4 and 5.
[11] An agent for improving a taurine modification rate of mitochondrial tRNALeu(UUR), comprising taurine as an active ingredient.
[12] The agent of [11], wherein the mitochondrial tRNALeu(UUR) is normal mitochondrial tRNALeu(UUR).
[13] The agent of [11], wherein the improvement of taurine modification rate is improvement of a total taurine modification rate determined from the following formula (1):
total taurine modification rate=τm5U/(U+τm5U)×100(%) (1)
wherein τm5U is an amount of a primer elongation product from tRNALeu(UUR) with taurine modification and U is an amount of a primer elongation product from tRNALeu(UUR) without taurine modification, and/or a normal taurine modification rate determined from the following formula (2):
normal taurine modification rate=total taurine modification rate/(100-mtDNA point mutation rate)/100(%) (2)
(in the above-mentioned formula, the mtDNA point mutation rate is the highest point mutation rate selected from the group consisting of point mutations at 14-position A (A3243G), 15-position G (G3244A), 29-position T (T3258C), 42-position T (T3271C) and 62-position T (T3291C) in a DNA encoding tRNALeu(UUR) shown in SEQ ID NO: 1).
[14] The agent of [11] or [12], which is a medicament or cosmetic.
[15] The agent of [11] or [12], which is a food with health claims or food additive.
[16] The agent of any of [11] to [15], which is for improving a taurine modification rate of mitochondrial tRNALeu(UUR) of a patient who developed a mitochondrial disease and/or a subject having an onset risk.
[17] The agent of [16], wherein the mitochondrial disease is caused by a mutation of a gene deficient in taurine modification of mitochondrial tRNALeu(UUR).
[18] The agent of [17], wherein the mutation of a gene deficient in taurine modification of mitochondrial tRNALeu(UUR) is a point mutation selected from the group consisting of the 14-position A (A3243G), the 15-position G (G3244A), the 29-position T (T3258C), the 42-position T (T3271C) and the 62-position T (T3291C) in a DNA encoding tRNALeu(UUR) shown in SEQ ID NO: 1).
[19] The agent of any of [16] to [18], wherein the mitochondrial disease is MELAS or diabetes.
The present inventors have found that the taurine modification rate of normal tRNALeu(UUR), among the mitochondrial tRNAs, correlates to aging, unlike the blood lactic acid value, ratio of blood lactic acid value to pyruvic acid value, cerebrospinal fluid lactic acid value, cerebrospinal fluid lactic acid value and pyruvic acid value, which are conventional markers of mitochondrial diseases. Therefore, the taurine modification rate of normal tRNALeu(UUR) is a universal marker capable of grasping the state of physiological function of not only mitochondrial disease patients but also healthy individuals.
In the present specification, indication of amino acid, (poly)peptide, (poly)nucleotide and the like using abbreviations follows the provision of IUPAC-IUB [IUPAC-IUB Communication on Biological Nomenclature, Eur. J. Biochem., 138: 9 (1984)], “Guideline for preparation of minute descriptions of compounds including base sequence or amino acid sequence” (ed. Japan Patent Office), and conventional symbols used in the pertinent field.
In the present invention, “senescence” means that biological functions decrease due to aging and other internal or external factors such as genetic factors, lifestyle and environmental factors and the like. Aging is physical progress of time from birth to death and is synonymous with chronological age. Such other internal factors include, for example, those relating to cellular senescence such as mitochondria function, peroxide radical concentration, telomere length and the like, and the like. Such other external factors include, for example, individual amount of motor activity, smoking or nonsmoking, dietary habits, nutritional status and the like. The biological function includes, for example, muscular strength, nerve conduction velocity, vital capacity, disease resistance and the like. Senescence due to aging generally starts after reaching the reproductive age, and starts from 20 to 30 years old in humans, though subject to individual differences. Senescence is considered to involve environmental factors and genetic predisposition that are intertwined complicatedly. The speed of such functional deterioration is not the same for all humans, and cannot necessarily be defined by the factor of aging alone.
Conventionally, therefore, there is no clear index of senescence. The index of senescence provided by the present invention can be used as the index also from the aspect of health expectancy.
The “senescence” in the present invention includes not only external changes such as reduction of height and body weight, change of skin and hair and the like, and what is called age-related decline in physical functions such as decline of motility functions, decline in sensory functions, decline in physiological functions and the like, but also senescence of cells constituting the living body (cellular senescence), and further, senescence of mitochondria that plays an important role in respiration and energy metabolism. When the taurine modification rate of mitochondrial tRNALeu(UUR) decreases due to senescence, the UUG codon-specific translation ability naturally becomes rate-limiting and the synthesis of proteins containing UUG codons decreases. This in turn decreases mitochondrial functions, and clearly decreases functions of the organs and the like that constitute the living body. When the decline of the modification rate proceeds further, for example, severe symptoms of dyspnea and skeletal muscle attenuation found in the elderly people are also considered to be developed in some cases. Therefore, it is needless to say that taurine modification rate of normal mitochondrial tRNALeu(UUR) can be used as an index of senescence and functional decline of mitochondria themselves, and is also useful as an index of the function of a living body, organ, tissue, cell or intracellular organelle, in particular, an index of senescence and functional decline of living body, organ, tissue, cell, or organelle with high energy demand.
In addition, the above-mentioned index is also useful for selection of subjects of taurine therapy currently under development for mitochondrial disease patients, use for companion diagnosis to be used for determination of the treatment effect thereof and assistance therefor.
The health expectancy here means a period defined by the Ministry of Health, Labor and Welfare, during which one can live without limitation on everyday life due to health problems. Each country including the World Health Organization aims to extend health expectancy, and it is desired to ultimately make the difference between the health expectancy and average life span close to zero.
In the present invention, mitochondrial tRNALeu(UUR) is a tRNA that is transcribed from mitochondrial DNA and recognizes the codon UUR (R is A or G) of leucine. In mitochondrial tRNALeu(UUR), the bases at the positions 17, 20 and 47 increase or decrease depending on the animal species, and therefore, the position of the nucleotide (UAA) corresponding to the anticodon is unified to be the 34-position to 36-position. DNA encoding human mitochondrial tRNALeu(UUR) is registered in NCBI and published under GenBank accession No. AB026838 (version AB026838.1) (SEQ ID NO: 1). The mitochondrial tRNALeu(UUR) transcribed from the DNA shown in SEQ ID NO: 1 is shown in SEQ ID NO: 2. The 36th (34-position according to the above-mentioned definition) uridine (U) of SEQ ID NO: 2 may or may not be taurine modified.
In the present specification, “mitochondrial tRNALeu(UUR)” is sometimes to be simply abbreviated as “tRNALeu(UUR)”.
Various mutations have been found in tRNALeu(UUR). In the present invention, the measurement target includes not only tRNALeu(UUR) shown in SEQ ID NO: 2 but also mutated tRNALeu(UUR) known to the present and mutated tRNALeu(UUR) to be found in the future. Specific examples of the mutated tRNALeu(UUR) include, in the DNA encoding tRNALeu(UUR) shown in SEQ ID NO: 1, point mutations at the 14-position A (A3243G), 15-position G (G3244A), 29-position T (T3258C), 42-position T (T3271C), 62-position T (T3291C): these mutations cause lack of taurine modification and are found in MELAS patients; point mutations at the 13-position G (A3242A), 21-position T (T3250C), 25-position C (C3254T), 51-position A (A3280G): these mutations have no effect on taurine modification and are found in mitochondrial diseases other than MELAS; and the like. For other mutations, MITOMAP (www.mitomap.org/MITOMAP) can be referred to.
In the present invention, mutated tRNALeu(UUR) refers to tRNALeu(UUR) transcribed from mtDNA having mutation causing deficiency of taurine modification and does not include tRNALeu(UUR) having mutation with no effect on taurine modification.
In addition, normal tRNALeu(UUR) refers to tRNALeu(UUR) other than the above-mentioned mutated tRNALeu(UUR). In human, tRNALeu(UUR) having the same base sequence as tRNALeu(UUR) shown in SEQ ID NO: 2 and tRNALeu(UUR) having a different base sequence from tRNALeu(UUR) shown in SEQ ID NO: 2 in which the difference in the base sequence does not influence the taurine modification of tRNALeu(UUR) are included. Those lacking the function of normal tRNALeu(UUR) are not included irrespective of the presence or absence of taurine modification.
The above-mentioned 14-position A, 15-position G, 29-position T, 42-position T and 62-position T are also conserved in gorilla, bovine, swine, dog, cat and the like besides human. In rat and mouse, they are similarly conserved except that the 42-position is C. Therefore, the mutation causing deficient taurine modification of tRNALeu(UUR) is not limited to human and the below-mentioned mammals such as primates, pets, domestic animals, experiment animals and the like can also be the targets.
In the present invention, taurine modification of mitochondrial tRNALeu(UUR) refers to post-transcriptional modification in which taurinomethyl group is bonded to the 5-position of the uracil base at the first letter of anticodon (UAA) of tRNALeu(UUR) (wobble position at the 34-position according to the above-mentioned definition). Uridine which is taurine-modified in this way is sometimes shown with abbreviation of τm5U.
Mitochondrial DNA (mtDNA) and Heteroplasmy
Some hundreds of mitochondria are present per cell, and each one of mitochondria contains 5 to 10 mitochondrial DNAs (mtDNAs). When constituted of a single mtDNA, it is called “homoplasmy”, and when normal and mutant mtDNAs are mixed, it is called “heteroplasmy”. When the ratio of mutated mtDNA (heteroplasmy degree) is high, mitochondrial respiration function becomes abnormal and a mitochondrial disease is developed. The degree of heteroplasmy varies depending on the tissues such as skeletal muscle, blood vessel, skin and the like, or cells. It was recently reported that tissues and cells of healthy human also contain a trace amount of mutated mtDNA (Brendan A. I. Payne et al.: Universal heteroplasmy of human mitochondrial DNA. Hum Mol Gent 22: 384-390 (2013)). In the present invention, therefore, the degree of taurine modification of mitochondrial tRNALeu(UUR) is defined as follows and the test subjects are divided into those having substantially normal mtDNA (healthy human) and those containing mutated mtDNA at a certain level (e.g., MELAS patients, diabetes patients), and taurine modification rate of tRNALeu(UUR) is measured.
Mitochondria of MELAS patients' cells are heteroplasmy and contain mutated mtDNA and normal mtDNA. Therefore, even if the first uracil in the anticodon of tRNALeu(UUR) transcribed from mutated mtDNA lacks taurine modification, tRNALeu(UUR) transcribed from normal mtDNA is assumed to be taurine modified.
The taurine modification rate of tRNALeu(UUR) transcribed from normal mtDNA contained in the cell derived from a test subject containing mutated mtDNA such as MELAS patients is defined as “normal taurine modification rate” and can be determined from the following formula (2) based on the “total taurine modification rate” determined from the following formula (1).
In the present invention, the total taurine modification rate is a value obtained by dividing taurine modified tRNALeu(UUR) in mitochondrial tRNALeu(UUR) in a sample derived from a test subject by a total sum of taurine modified tRNALeu(UUR) and taurine non-modified tRNALeu(UUR).
The test subjects here are mammals including human. Examples of the mammal include rodents such as mouse, rat, hamster, guinea pig and the like, experiment animals such as rabbit and the like, domestic animals such as swine, bovine, goat, horse, sheep, mink and the like, pets such as dog, cat and the like, primates such as human, monkey, Macaca fascicularis, Macaca mulatta, marmoset, orangutan, chimpanzee, gorilla and the like, and the like. The sample derived from a test subject is not particularly limited as long as it can be collected from mammals, preferably human, and body fluid samples such as blood, lymph fluid, urine and the like, and biopsy tissues such as hair, buccal mucosa, stomach, large intestine, lung, liver, brain and the like can be mentioned. Preferred is a blood sample, and leukocyte in a blood sample is more preferable.
The total taurine modification rate is a value obtained by indirectly determining the amounts of taurine modified tRNALeu(UUR) and taurine non-modified tRNALeu(UUR) by measuring the amount of a primer elongation product by a reverse transcription reaction (primer elongation method) using a primer, and assigning them in the following formula (1):
total taurine modification rate=τm5U/(U+τm5U)×100(%) (1)
wherein τm5U is an amount of primer elongation product from tRNALeu(UUR) with taurine modification and U is an amount of a primer elongation product from tRNALeu(UUR) without taurine modification.
When the test subject is suspected to have a mutated mitochondrial DNA having a single base substitution selected from the group consisting of A3243G, T3271C, G3244A, T3258C and T3291C in the tRNALeu(UUR) gene coding region, a normal taurine modification rate is determined by the following formula (2):
normal taurine modification rate=total taurine modification rate/(100-mtDNA point mutation rate)/100(%) (2)
(in the above-mentioned formula, the mtDNA point mutation rate is the highest point mutation rate selected from the group consisting of point mutations at 14-position A (A3243G), 15-position G (G3244A), 29-position T (T3258C), 42-position T (T3271C) and 62-position T (T3291C) in a DNA encoding tRNALeu(UUR) shown in SEQ ID NO: 1) successively from the aforementioned formula (1) and desirably used as the index of senescence.
For the analysis of point mutation rate of mtDNA, DNA sequencing method, PCR-RFLP method, PCR-SSCP method, denaturing high-performance liquid chromatography (DHPLC) method, BiPlex Invader method, SnaP shot method, high-resolution melt (HRM) profiling method, temporal temperature gradient gel electrophoresis (TTGE) method, a method using a next-generation sequencer currently under development and the like can be mentioned.
The total taurine modification rate is theoretically within the range of 0-100%. Considering the pathology of MELAS patients, severe symptoms may be developed when the total taurine modification rate decreases. On the other hand, when the normal taurine modification rate is calculated using the aforementioned calculation formula (2), it is almost the same as the total taurine modification rate because the mtDNA point mutation rate is almost 0% in healthy human. However, the normal taurine modification rate of mitochondrial disease patients may exceed 100% by calculation due to mtDNA point mutation rate.
In the doctor-initiated clinical trial, the normal taurine modification rate of tRNALeu(UUR) was plotted on the vertical axis and the age of the test subject on the horizontal axis. Thus, it was found that the normal taurine modification rate decreased as the age of the test subject increased (
It can be judged that a lower normal taurine modification rate indicates further progression of senescence. That is, the normal taurine modification rate can be used to indicate the measure of senescence as “Taurine Age”. In healthy human, the total taurine modification rate is close to normal taurine modification rate, and the total taurine modification rate can be conveniently used to indicate the senescence degree as “taurine age”.
(1) a step of measuring a level of taurine modification of mitochondrial tRNALeu(UUR) in a biological sample isolated from a test subject, by a reverse transcription reaction from a primer with the tRNALeu(UUR) as a template
Non-limitative examples of the biological sample to be the measurement target include biopsy tissues of hair, buccal mucosa, stomach, large intestine, lung, liver, brain and the like, and body fluid samples of blood, lymph fluid, urine and the like. Blood is preferable since it is easily collected, and leukocyte obtained from blood is more preferable. In the following, the measurement method of senescence is explained by taking leukocyte as an example. Other biological samples can also be measured similarly.
The leukocyte to be measured can be obtained by collecting blood from a test subject and recovering the leukocyte fraction by a conventional method. For this purpose, commercially available reagents can be preferably used. Examples of the commercially available reagent include Lymphoprep (registered trade mark), Ficoll (registered trade mark)-Paque and the like. The leukocyte fraction is obtained by performing density gradient centrifugation according to the instructions of the manufacturer of the reagent and separating the blood cell layer including the lymphocytes and monocytes (peripheral blood mononuclear cell: PBMC).
The test subject is typically human, and may be a mammal excluding human. Examples of the mammal excluding human include rodents such as mouse, rat, hamster, guinea pig and the like, experiment animals such as rabbit and the like, domestic animals such as swine, bovine, goat, horse, sheep, mink and the like, pets such as dog, cat and the like, primates such as monkey, Macaca fascicularis, Macaca mulatta, marmoset, orangutan, chimpanzee, gorilla and the like, and the like.
A sample containing RNA is prepared from a leukocyte fraction derived from the test subject by a conventional method. As a method of extracting RNA from cells, it is desirable to adopt a method of simultaneously performing cell disruption and inactivation of RNase. Cells are disrupted and solubilized with a solubilizing agent, proteins are removed with a denaturing agent, gene is precipitated with ethanol or the like, and RNA can be prepared from leukocytes. Commercially available extraction kits can be preferably used for this operation. For example, Isogen (manufactured by Nippon Gene), Trizol (manufactured by Ambion) and the like can be mentioned.
The obtained RNA can be subjected to a reverse transcription reaction without further purification. To use tRNALeu(UUR) contained in the obtained RNA as a template, a primer that specifically hybridizes to the tRNALeu(UUR) is used. In the present invention, the primer is an oligonucleotide complementary to the template. As the oligonucleotide, DNA, RNA, hybrid of DNA and RNA may be used. From the aspect of operability, DNA is preferable. The nucleotide constituting the oligonucleotide may be a natural nucleotide or an artificial nucleotide.
The length of the primer is not particularly limited as long as it can retain a function capable of specifically hybridizing to tRNALeu(UUR). It is 8-30 bases in length, preferably 10-25 bases in length, more preferably 10-22 bases in length.
The specific base sequence of the primer is designed such that the length of the primer elongation product differs depending on the presence or absence of taurine modification of tRNALeu(UUR), or the length of the primer elongation product is different from that of the base sequence. A preferable base sequence is a DNA comprising the base sequence shown in the following:
In the primer, within the range of the object of the present invention, one or more (e.g., 2) bases may be added to the 5′-terminal and/or 3′-terminal and one or more (e.g., 2) bases may be deleted from the 5′-terminal and/or 3′-terminal in the base sequence shown in SEQ ID NO: 3.
Furthermore, when the measurement target tRNALeu(UUR) is assumed to have a mutated base sequence at a position hybridizing with the primer, any base in the base sequence shown in SEQ ID NO: 3 may be substituted with other base such that it becomes complementary to the base sequence of the mutated tRNALeu(UUR). To be specific, DNA containing a base sequence of the following case:
The aforementioned primer may be directly or indirectly labeled with a labeling substance. Examples of the labeling substance include fluorescent substance (e.g., FITC, rhodamine, FAM™, VIC™, NED™, PET™, the aforementioned 4 kinds are trade names of Applied Biosystems Inc.), radioactive substance (e.g., 32P, 35S, 14C, 3H), enzyme (e.g., alkaliphosphatase, peroxidase), colored particles (e.g., colloidal metal particles, colored latex), biotin and the like. Preferred is a fluorescent substance or a radioactive substance, and the labeling site is desirably the 5′-terminal of the primer.
The reverse transcription reaction can be performed by a known method while referring to Molecular Cloning: A Laboratory Manual, Fourth Edition (2012) and the like. The reverse transcription reaction is performed using reverse transcriptase, the above-mentioned primer and dNTP (nucleotide mixture) in the co-presence of an RNase inhibitor where necessary, and using tRNALeu(UUR) contained in the obtained RNA as a template.
Reverse transcriptase is commercially available, and a commercially available enzyme kit can be used as long as it is an enzyme capable of performing a reverse transcription reaction using tRNALeu(UUR) as a template. For example, AMV reverse transcriptase, M-MuLV reverse transcriptase and the like can be mentioned. Mutated reverse transcriptase such as SuperscriptIII (manufactured by Thermo Fisher Scientific Inc.) cannot be used since the reaction is not discontinued at a taurine modification site.
About 1 pg-1 μg as total RNA is used as the template RNA.
About 0.1-1 μg of the primer is used.
As dNTP, a mixture of 4 kinds of nucleotides (e.g., dATP, dGTP, dCTP, dTTP) may be used, or 1-3 kinds complementary to the base sequence of the template may also be used. dNTP is generally used at a concentration of about 1-500 μM per nucleotide.
The RNase inhibitor can be used without limitation as long as it can inhibit RNase under the conditions of reverse transcription reaction. Various RNase inhibitors are commercially available and examples of the commercially available product include RNaseOUT (manufactured by Thermo Fisher Scientific Inc.), RNasin (manufactured by Promega) and the like.
The composition of the reverse transcription reaction solution can be appropriately set depending on the reverse transcriptase to be used. In addition, the reaction buffer attached to the commercially available enzyme kit can be diluted and used.
The reverse transcription reaction is divided into an annealing reaction of a template and a primer and a successive elongation reaction from the primer.
In one embodiment of the annealing reaction, for example, conditions for incubation at about 80° C. for 1-5 min, and standing still at not more than 37° C., generally room temperature (about 25° C.) for 10 min-several hours can be mentioned.
In one embodiment of the primer elongation reaction, for example, it is performed at 42° C.-60° C. for 15 min-2 hr and after completion of the reaction, and a heat treatment is performed at 95° C. for 1-5 min, whereby reverse transcriptase is deactivated.
After completion of the reverse transcription reaction, a difference in the primer elongation product is detected by the presence or absence of taurine modification. For example, a method in which a primer elongation product is developed on agarose gel or polyacrylamide gel by electrophoresis and then detected by a difference in size can be mentioned. In this case, the 5′ terminal of the primer is fluorescence labeled or radiolabeled in advance, and after electrophoresis, the signal is taken on an imaging plate and detected using an appropriate detection device.
Here, when a reverse transcription reaction is carried out using a primer containing the base sequence shown in SEQ ID NO: 3, τm5U modification acts as a barricade against elongation reaction, and the elongation reaction of tRNALeu(UUR) with taurine modification is discontinued at the 35-position U. In the case of tRNALeu(UUR) without taurine modification, steric hindrance against elongation reaction is absent and the elongation reaction proceeds, and the elongation reaction can be discontinued at a desired position by the co-presence of dideoxynucleotide (e.g., ddA, ddG, ddC, ddT) in the reaction mixture. For example, when ddG is used, as shown in
Furthermore, a band separated by electrophoresis may be cut out, the base sequence is determined by a conventional method, and the band may be identified by measuring the difference in the base sequence of the primer elongation product by the presence or absence of taurine modification.
(2) a step of calculating a quantitative ratio of a primer elongation product from tRNALeu(UUR) with taurine modification and a primer elongation product from tRNALeu(UUR) without taurine modification
After electrophoresis of primer elongation product in the aforementioned step, the signal taken into the imaging plate is quantified using densitometry such as BAS 2000 imaging analyzer (manufactured by GE Healthcare) and the like.
The amounts of a primer elongation product from tRNALeu(UUR) with taurine modification and a primer elongation product from tRNALeu(UUR) without taurine modification can be expressed in any unit, or may be expressed by a quantitative ratio. These values are assigned in the following formula (1):
total taurine modification rate=τm5U/(U+τm5U)×100(%) (1)
wherein τm5U is an amount of primer elongation product from tRNALeu(UUR) with taurine modification and U is an amount of a primer elongation product from tRNALeu(UUR) without taurine modification, of the total taurine modification rate is calculated.
When the test subject is suspected to have mutated mtDNA, a normal taurine modification rate is determined by the following formula (2):
normal taurine modification rate=total taurine modification rate/(100-mtDNA point mutation rate)/100(%) (2)
(in the above-mentioned formula, the mtDNA point mutation rate is the highest point mutation rate selected from the group consisting of point mutations at 14-position A (A3243G), 15-position G (G3244A), 29-position T (T3258C), 42-position T (T3271C) and 62-position T (T3291C) in a DNA encoding tRNALeu(UUR) shown in SEQ ID NO: 1) and desirably used as the index of senescence.
The point mutation rate of mtDNA can be measured using DNA sequencing method, PCR-RFLP method, PCR-SSCP method, denaturing high-performance liquid chromatography (DHPLC) method, BiPlex Invader method, SnaP shot method, high-resolution melt (HRM) profiling method, temporal temperature gradient gel electrophoresis (TTGE) method, a method using a next-generation sequencer currently under development and the like.
For example, in the case of MELAS patients having A3243G, a PCR product amplified using the PCR-RFLP method can be used to quantify the difference in length of the band obtained by the presence or absence of the cleavage site of restriction enzyme ApaI (PCR product with mutation has cleavage site, PCR product without mutation does not have cleavage site), and the point mutation rate of A3243G can be measured. In the case of MELAS patients having I3271C, a PCR product amplified using the PCR-RFLP method can be used to quantify the difference in length of the band obtained by the presence or absence of the cleavage site of restriction enzyme AflII (PCR product with mutation has cleavage site, PCR product without mutation does not have cleavage site), and the point mutation rate of T3271C can be measured.
The thus-obtained total taurine modification rate and normal taurine modification rate can be used as an index of senescence in the present invention. The total taurine modification rate and normal taurine modification rate of healthy subject are almost the same, thus the total taurine modification rate can be used as an index of senescence.
The total taurine modification rate of 100% can be judged to be young from the viewpoint of taurine age.
In the analysis results of MELAS patients, it has been newly shown that a decrease in the taurine modification rate of normal mitochondrial tRNALeu(UUR) has a certain correlation with the chronological age of the patient (
In rare cases, taurine modification rates of normal mitochondrial tRNALeu(UUR) not correlated with chronological age are observed in healthy subjects and MELAS patients. Therefore, the taurine modification rate of normal mitochondrial tRNALeu(UUR) is not only a mere index of age-related senescence of a test subject but can also be utilized as an index of senescence of the whole physical functions reflecting the health condition of the test subject including the presence or absence of diseases, such as nutritional state, metabolic abnormality and the like, or an index of health expectancy, in particular, health expectancy without any specific cause of death.
In addition, the taurine modification rate of normal mitochondrial tRNALeu(UUR) is also useful as a biomarker used for determining whether the test subject is normal or has a presymptomatic disease, whether the living conditions of the test subject need improvement, whether a treatment is necessary, and in an assistance method therefor.
The effectiveness of taurine administration has been confirmed not only in MELAS patients but diabetes patients having single base substitution (A3243G) of mitochondrial tRNALeu(UUR). It has been shown that the taurine modification rate of normal mitochondrial tRNALeu(UUR) is also useful as an innovative novel biomarker for selection of subjects of taurine therapy for the mitochondrial disease patients currently under development, application to companion diagnosis used for determination of the therapeutic effects thereof and assistance therefor.
The primer comprising a base sequence consisting of 10-25 bases and complementary to the mitochondrial tRNALeu(UUR) which is contained in the senescence determining drug of the present invention, is the same as the primer described in “measurement method of senescence”.
The primer may be contained in a freeze-dried state or in a solution state together with a pharmaceutically acceptable carrier.
When the determining drug of the present invention is prepared as a liquid preparation, the pharmaceutically acceptable carrier includes various carriers conventionally used as a preparation material, such as diluent, solvent, solubilizing agent, isotonizing agent, buffering agent and the like.
As the diluent, water, physiological saline and the like can be mentioned.
As the solvent, water, physiological saline, ethanol and the like can be mentioned.
As the solubilizing agent, cyclodextrins and the like can be mentioned.
As the isotonizing agent, inorganic salts such as sodium chloride, potassium chloride and the like, and carbohydrates such as glycerin, mannitol, sorbitol and the like can be mentioned.
As the buffering agent, phosphate buffer, acetate buffer, borate buffer, carbonate buffer, citrate buffer, Tris buffer and the like can be mentioned.
The mixing ratio of these carriers can be appropriately determined by those skilled in the art.
The primer is desirably kept frozen or on ice until immediately before use.
The senescence determining kit of the present invention contains a primer comprising a base sequence consisting of 10-25 bases and complementary to the mitochondrial tRNALeu(UUR) and a reverse transcriptase.
The primer comprising a base sequence consisting of 10-25 bases and complementary to the mitochondrial tRNALeu(UUR), which is contained in the senescence determining kit of the present invention, is the same as the primer described in “measurement method of senescence”.
Preferred embodiments and specific examples of the above-mentioned reverse transcriptase are as described in “measurement method of senescence”.
The kit of the present invention may further contain nucleoside triphosphoric acid, buffer for primer elongation reaction, RNase inhibitor.
Nucleoside triphosphoric acid is a substrate incorporated in a primer to constitute a primer elongation product and is generally used as a dNTP mixture. The dNTP mixture is typically composed of dATP, dTTP, dCTP and dGTP.
Where necessary, at least one kind of dideoxynucleotide (ddATP, ddTTP, ddCTP, ddGTP) for discontinuing primer elongation at a desired site may be contained.
Examples of the aforementioned buffer include buffers used for carrying out a general hybridization reaction such as tris buffer, phosphate buffer, veronal buffer, borate buffer, Good's buffer and the like. While the pH thereof is not particularly limited, it is generally preferably 5-9.
The aforementioned RNase inhibitor is the same as the RNase inhibitor described in “senescence measurement method”.
The kit of the present invention may further contain, in addition to the above-mentioned primer and the like, reaction container, buffer for diluting primer, positive control (e.g., healthy human-derived cybrid cell RNA: see Proc Natl Acad Sci USA. 2005; 102(20):7127-7132), negative control (e.g., MELAS patient-derived cybrid cell RNA: see Proc Natl Acad Sci USA. 2005; 102(20):7127-7132), manufacturer's instructions describing protocol and the like.
Agent for Improving Taurine Modification Rate of Mitochondrial tRNALeu(UUR)
A decrease in the taurine modification rate of normal mitochondrial tRNALeu(UUR) due to aging can be improved by taurine administration. The results of Test Example 2 indicate that taurine and a composition containing same are useful for improving taurine modification rate of mitochondrial tRNALeu(UUR) preventing a decrease in the taurine modification rate of mitochondrial tRNALeu(UUR), particularly as a pharmaceutical product, quasi-drug, cosmetic or food for improving the taurine modification rate of normal mitochondrial tRNALeu(UUR) that decreased due to aging.
The improving agent of the present invention contains taurine as an active ingredient. Taurine is also referred to as aminoethylsulfonic acid or 2-aminoethanesulfonic acid. Taurine may be organically synthesized according to a conventional method or may be a natural product extracted and isolated from animals and plants.
Taurine may be in the form of a taurine derivative as long as it acts as taurine in vivo. Examples of the taurine derivative include N-methyltaurine, N,N-dimethyltaurine, N,N,N-trimethyltaurine, guanidinoethanesulfonic acid, guanidinoethanesulfinic acid, N-(2-acetamide)-2-aminoethanesulfonic acid, piperazino-N,N′-bis(2-ethanesulfonic acid), N-[1′-aza-cycloheptane-2′-yl]-2-aminoethanesulfonic acid, N-[1′-aza-cyclopentane-2′-yl]-2-aminoethanesulfonic acid, N-[1′-aza-cycloheptane-2′-yl]-3-aminopropanesulfonic acid, N-[1′-aza-cyclopentane-2′-yl]-3-aminopropanesulfonic acid, 2-aminoethylphosphonic acid, 3-aminopropionic acid, ethanolamine-O-sulfate, aminomethanesulfonic acid, homotaurine, pyridine-3-sulfonic acid, piperidine-3-sulfonic acid, aniline-2-sulfonic acid, (±)-2-aminocyclohexanesulfonic acid, 2-aminocyclopentanesulfonic acid, quinoline-8-sulfonic acid, 1,2,3,4-tetrahydroquinoline-8-sulfonic acid, 3-amino-bicyclo[2.2.1]heptane-2-sulfonic acid, 6-aminomethyl-3-methyl-4-1,2,4-benzothiadiazine-, 1-dioxide (TAG), glycine, retinylidene taurine(TAURET)3-acetamide-1-propanesulfonic acid Ca salt (ACAMPROSATE), 5-taurinomethyluridine, 5-taurinomethyl-2-thiouridine, isethionic acid, cysteinesulfonic acid, ritralon, 2-amino-3-hydroxy-1-propanesulfonic acid, N-(2,3-dihydroxy-n-propyl)taurine, decanoylsarcosyl taurine and the like.
The taurine modification rate in a test subject is improved by administration or ingestion of the improving agent of the present invention to or by the test subject, as compared to before administration or ingestion. The taurine modification rate to be improved here is a total taurine modification rate represented by the aforementioned formula (1) and/or a normal taurine modification rate represented by the aforementioned formula (2).
For such object, the improving agent of the present invention contains taurine alone, or also contains excipient (e.g., lactose, sucrose, starch, cyclodextrin etc.) and, in some cases, flavor, dye, seasoning, stabilizer, preservative and the like. It is formulated as tablet, pill, granule, fine granule, powder, pellet, capsule, solution, milky lotion, suspension, syrup, lozenge and the like and can be used as medicament, quasi-drug, cosmetic or food (preferably, food with health claims) or food additive. The improving agent of the present invention can also be used as a research reagent.
The amount of taurine contained in the improving agent of the present invention is not particularly limited as long as it affords the effect of the present invention, and is generally 0.0001-100 wt %, preferably 0.001-99.0 wt %.
The effective amount of taurine can be shown as a daily amount of taurine per 1 kg body weight. A recommended effective amount is 0.01-1.0 g/kg body weight/day, preferably 0.02-0.5 g/kg body weight/day.
When the improving agent of the present invention is used as a medicament, it preferably contains an effective amount of taurine and a pharmaceutically acceptable carrier.
Examples of the pharmaceutically acceptable carrier include, but are not limited to, excipient (e.g., lactose, sucrose, dextrin, hydroxypropylcellulose, polyvinylpyrrolidone, light anhydrous silicic acid etc.), disintegrant (e.g., starch, carboxymethylcellulose etc.), lubricant (e.g., magnesium stearate, talc etc.), surfactant (e.g., polyoxyethylene hydrogenated castor oil, glycerol monostearate, sodium lauryl sulfate, macrogols, sucrose fatty acid ester etc.), solvent (e.g., water, brine, soybean oil etc.), preservative (e.g., p-hydroxybenzoic acid ester etc.) and the like.
The improving agent of the present invention can be safely administered orally or parenterally to an animal (e.g., mammal, birds, fish etc.).
The improving agent of the present invention can also be ingested as a food or food additive. The “food” in the present invention means food in general, which includes general food including what is called health food, as well as food with health claims such as food for specified health use and food with nutrient function claims, specified in the Food with health claims system by the Japanese Ministry of Health, Labour and Welfare, which may be a food with health claim or health highlighting. The food of the present invention further encompasses supplements, feed/prey and the like.
When used for foods, taurine can also be used by adding to, for example, general foods (including so-called health foods) such as beverage, bread, confectionery and the like. In addition, taurine is formulated together with excipient (e.g., lactose, sucrose, starch etc.) and, in some cases, flavor, dye and the like into tablet, pill, granule, fine granule, powder, pellet, capsule, solution, milky lotion, suspension, syrup, lozenge and the like and can be used as food with health claims such as food for specified health uses, food with nutrient function claims and the like, or supplement. In addition, the food and food additive of the present invention can also be applied to feed/prey use, and can be given or administered to poultry, domestic animals and the like by adding to general feed/prey.
When ingested as a food or feed/prey, general number of ingestion times of food or feed/prey per day and general amount of ingestion for one time are calculated, the daily intake is defined and the amount of taurine contained in the daily intake amount of the food or feed/prey is determined. The content of taurine can be determined based on the below-mentioned doses.
The ingestion or administration amount of the improving agent of the present invention varies depending on the age, body weight and health condition of the subject of ingestion or administration and cannot be determined unconditionally. For example, when aiming at maintaining, promoting or improving health, the agent is generally formulated in the form of a quasi-drug such as drink agent and the like, food or cosmetic.
When treatment of disorders caused by a decrease in the taurine modification rate or health recovery is aimed, the agent is generally formulated in the form of a pharmaceutical product, quasi-drug or food. It is preferable to give or administer 0.4-40 g, preferably 0.8 g-20 g, more preferably 4.0-15 g, as taurine per day for an adult in one to several portions per day.
When the body weight is 40 kg or below, it is preferable to generally give or administer 0.3-30 g, preferably 0.6 g-15 g, more preferably 3.0-12 g, per day in one to several portions per day.
The administration method of the improving agent (medicament) of the present invention is not particularly limited as long as it is a route affording a prophylactic or therapeutic effect on a decrease in the taurine modification rate. For example, the agent can be administered parenterally (intravenous administration, intramuscular administration, direct administration into tissues, intranasal administration, intradermal administration, transdermal administration, intraperitoneal administration, gastrostomy, tube administration, enteral nutrition administration and the like) or orally. Particularly, when the medicament is applied to human, it can be administered intravenously, intramuscularly or orally. The dosage form is not particularly limited, and various administration dosage forms, for example, oral preparation (granule, powder, tablet, capsule, syrup, emulsion, suspension, drink agent and the like), injection, drip infusion, external preparation (preparations for nasal administration, dermal preparation, ointment and the like) can be used for administration. An external preparation (dermal preparation, ointment and the like) can also be administered as a quasi-drug or cosmetic.
An agent for improving taurine modification rate of mitochondrial tRNALeu(UUR) of the present invention may be used as an agent for improving the taurine modification rate of mitochondrial tRNALeu(UUR) that has decreased due to aging and the state of biological function due to genetic factors and lifestyle and environmental factors, and the like, in patients who developed mitochondrial diseases, preferably, patients who developed mitochondrial diseases due to the mutation of a gene deficient in taurine modification of mitochondrial tRNALeu(UUR) more preferably patients who developed mitochondrial diseases due to a point mutation selected from the group consisting of the 14-position A (A3243G), the 15-position G (G3244A), the 29-position T (T3258C), the 42-position T (T3271C) and the 62-position T (T3291C) in a DNA shown in SEQ ID NO: 1 and encoding tRNALeu(UUR), particularly preferably patients who developed mitochondrial diseases due to a point mutation at the 14-position A (A3243G) in a DNA shown in SEQ ID NO: 1 and encoding tRNALeu(UUR), particularly, patients who developed MELAS or diabetes or a subject having a risk thereof. Furthermore, the improving agent of the present invention may also be used as an agent for improving the taurine modification rate of mitochondrial tRNALeu(UUR) that has decreased due to aging and the state of biological function due to genetic factors, lifestyle and environmental factors, and the like, in these targets and patients. In addition, the agent for improving taurine modification rate of mitochondrial tRNALeu(UUR) of the present invention is particularly useful not only for the improvement of abnormal taurine modification rate of mitochondrial tRNALeu(UUR), but also for the improvement of a decrease in the taurine modification rate of normal mitochondrial tRNALeu(UUR).
The present invention is explained in more detail in the following by referring to Examples. The present invention is not limited thereto in any way.
A written informed consent was obtained from MELAS patients who participated in the clinical trial and patient blood was collected. Crude RNA was obtained from the collected blood by using Isogen (manufactured by Nippon Gene) according to the manufacturer's instructions.
Handling of patients' blood also followed the ethical regulations at Kawasaki Medical School.
Basically, the method of Kirino et al. (Proc Natl Acad Sci USA. 2005; 102(20): 7127-7132) was followed. The principle of the primer elongation method by Kirino et al. is shown in
The base sequence of the primer used is as described below.
The base sequences of the two predicted primer elongation products are as follows.
The 5′-terminal of the above-mentioned primer and primer elongation product is labeled with 32P in this Example.
Using RNA (0.2-1 μg) obtained from the leukocyte of the test subject as a template, the primer was annealed by incubating with 32P-labeled primer (SEQ ID NO: 3, 0.1 pmol) corresponding to the 3′ side of the anticodon of tRNALeu(UUR) at 80° C. for 2 min, and standing the mixture at room temperature for 1 hr. Thereafter, in a reaction buffer for reverse transcriptase (manufactured by Invitrogen), dATP, dTTP, ddGTP (each 1.5 mM, manufactured by AmershamPharmacia) were added (final concentration 37.5 μM), M-MuLV Reverse transcriptase (RNase H−) 1 μL (40 units/μL, manufactured by Invitrogen) was mixed and a reverse transcription reaction was performed at 42° C. for 1 hr. In the case of MELAS patients having T3271C mutation, 32P-labeled primers (mix primer, 0.1 pmol) shown in SEQ ID NO: 3 and SEQ ID NO: 4 were used.
After completion of the reaction, the reaction mixture was subjected to 15% polyacrylamide electrophoresis containing 7M urea. The band labeled with RI was visualized with BAS5000 bio-imaging analyzer (manufactured by Fuji Film).
When the anticodon (first letter U: indicated by underline in
Since MELAS patients who participated in doctor-initiated clinical trials had A3243G mutation or T3271C mutation, these point mutation rates were determined as follows. A partially-modified PCR-RFLP method of Goto et al. was used (Goto Y. et al.: A new mtDNA mutation associated with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). Biochimica et Biophysica Acta 1097: 238-240 (1991)). For detection of A3243G mutation, PCR was performed using two primers of
The PCR product cleaved with the above-mentioned restriction enzyme was subjected to 15% polyacrylamide electrophoresis, the separated band was stained with ethidium bromide, the intensity of the band was quantified using a densitometer, and the point mutation rate was determined (Table 1).
Using the above-mentioned total taurine modification rate and point mutation rate, the normal taurine modification rate of MELAS patients was determined. The results are shown in
Measurement of the lactic acid value in the blood and in the cerebrospinal fluid was performed by reacting lactic acid oxidase with L-lactic acid and quantifying the resulting hydrogen peroxide by colorimetrically measuring the dye generated in the presence of peroxidase.
The pyruvic acid value was determined by reacting pyruvic acid oxidase with pyruvic acid and measuring the generated hydrogen peroxide by colorimetrically measuring the dye generated in the presence of peroxidase.
Taurine modification rate of mitochondrial tRNALeu(UUR) in blood leukocytes of patients participating in the clinical trial was measured and show graphically with the age of the test subject plotted as the horizontal axis. As a result, the total taurine modification rate and the age were not correlated, whereas the normal taurine modification rate decreased in an age-dependent manner (
In the above-mentioned doctor-initiated clinical trial, taurine was administered to MELAS patients. The dose was 12 g/day for test subjects weighing not less than 40 kg, 9 g/day for not less than 25 kg to less than 40 kg, and the dosing period was 52 weeks (1 year). Blood was collected from the test subject at the end date of the taurine administration (52 weeks), and the total taurine modification rate and the normal taurine modification rate were measured according to the method described in Example 1. The results are shown in
The results of Example 1 and Test Example 2 show that the taurine modification rate of normal mitochondrial tRNALeu(UUR) decreases with aging and that the decreased taurine modification rate increases by oral administration of taurine. Furthermore, the presence of cases in which the taurine modification rate of normal tRNALeu(UUR) exceeds 100% indicates that the taurine modification rate of mutated tRNALeu(UUR) is also improved by oral administration of taurine.
The cause of the onset of MELAS has heretofore been considered to be the lack of taurine modification of mutated tRNALeu(UUR); however, this result suggests that the onset of MELAS involves a decrease in the taurine modification rate of normal tRNALeu(UUR) due to aging.
As is well known, taurine modification function of tRNALeu(UUR) itself is not deficient in MELAS patients.
While the phenomenon observed in Example 1 is the analysis result of MELAS patients, it can be said to reflect a phenomenon that occurs similarly in healthy subjects as well. That is, the taurine modification rate of tRNALeu(UUR) can be used as a biomarker of mitochondrial senescence.
When the taurine modification rate of mitochondrial tRNALeu(UUR) decreases along with senescence, the UUG codon-specific translation ability naturally becomes rate-limiting and synthesis of the whole protein including the UUG codon decreases. It is obvious that, along with that, the mitochondrial function that provides an important function in respiration and energy metabolism declines, and the functions of the living body, the organs constituting the living body and the like deteriorate. If the decline of the modification rate progresses, for example, serious symptoms such as dyspnea and attenuation of skeletal muscle found in elderly people are considered to be developed in some cases.
Therefore, the results of Example 1 and Test Examples show that the taurine modification rate of normal mitochondrial tRNALeu(UUR) is also useful as an index of the functions of living organisms, organs, tissues, cells or intracellular organella, in particular, as an index of senescence and functional deterioration of living organisms and organs, tissues, cells or intracellular organelle having high energy demand, not to mention that it can be used as an index of senescence and functional deterioration of mitochondrion itself. In addition, cases with lower normal taurine modification rate than that corresponding to the chronological age as in Test Example 2 with a patient having a test subject age of 14 and cases with relatively high normal taurine modification rate despite a relatively high chronological age as in the patient having a test subject age of 46 are observed, and there is a considerable range in the normal taurine modification rate of the young healthy subjects of the below-mentioned Test Example 4. Therefore, it is shown that the normal taurine modification rate is not only a mere index of age-related senescence of a test subject but also utilizable as an index of senescence reflecting the health condition of a test subject including nutritional state, the presence or absence of a disease such as metabolic abnormality and the like, and the like, or as an index of health expectancy, in particular, health expectancy without any specific cause of death.
Furthermore, a decrease in the taurine modification rate of normal mitochondrial tRNALeu(UUR), which is associated with senescence due to aging and the like, can be improved by administration of taurine. Thus, the results of Test Example 2 and the below-mentioned Test Example 3 show that taurine and a composition containing same are useful as pharmaceutical products, quasi-drugs, cosmetics or foods for improving the taurine modification rate of mitochondrial tRNALeu(UUR), preventing a decrease in the taurine modification rate of mitochondrial tRNALeu(UUR), in particular, improving taurine modification rate of normal mitochondrial tRNALeu(UUR) that decreased due to aging.
In Test Example 2, the disease state was improved by taurine administration in MELAS patients due to single base mutation (A3243G) of mitochondrial gene. Thus, the treatment effect of taurine administration on diabetes caused by the same single base mutation (A3243G) of mitochondrial gene was confirmed. To be specific, taurine (trade name taurine powder 98% “Taisho”, manufactured by Taisho Pharmaceutical Co. Ltd.) was orally administered every day to a patient (49 years old, female) diagnosed to have diabetes due to single base mutation (A3243G) of mitochondrial gene and having cardiomyopathy in association therewith. Administered was taurine at 4 g/administration, 3 times/day (12 g/day), and the dosing period was about one year. Blood was collected from this patient over time from the start to the end of taurine administration, and the value of hemoglobin Alc (HbAlc), which is a diabetic marker, was measured. As a result, the value of 7.7% at the start decreased to 6.9% at week 23 (about 5 months) from the start of administration and 6.8% at the end of administration. As the above-mentioned results show, the value of HbAlc of this patient was controlled to less than 7%, which is the desired value for preventing complications of diabetes, throughout the taurine administration period. Furthermore, 12 units of insulin administration necessary at the start of taurine administration could be reduced to 9 units at the end of administration, and it was confirmed that oral administration of taurine can improve the symptoms of diabetes patients due to mitochondrial gene mutation.
As is clear from the below-mentioned Test Example 4, a decrease in the taurine modification rate of normal mitochondrial tRNALeu(UUR) caused by aging and the state of biological function due to genetic factors, lifestyle and environmental factors, and the like is not limited to MELAS but is a universal phenomenon in healthy subjects as well. Thus, the mechanism of the onset of diabetes due to mitochondrial gene mutation is considered to be based on a decrease in the taurine modification rate of normal mitochondrial tRNALeu(UUR) in addition to abnormal mitochondrial tRNALeu(UUR), similar to the case of MELAS. Therefore, also in the case of diabetes, the clinical symptoms can be considered to have been improved by the improvement of taurine modification rate of normal mitochondrial tRNALeu(UUR) in addition to the improvement of taurine modification rate of abnormal mitochondrial tRNALeu(UUR) by taurine administration.
In Test Example 2, it was confirmed that the taurine modification rate of normal mitochondrial tRNALeu(UUR) decreases with aging in MELAS patients. Thus, it was confirmed that the taurine modification rate of normal mitochondrial tRNALeu(UUR) similarly decreases with aging in healthy subjects as well by a method similar to that in Test Example 2. The results thereof are shown in
The above-mentioned Test Examples show that the taurine modification rate of normal mitochondrial tRNALeu(UUR) universally decreases with senescence due to aging or by an influence of genetic factors, lifestyle and environmental factors and the like, both in mitochondrial disease patients and healthy subjects.
In addition, it was confirmed that a decrease in the aforementioned taurine modification rate is improved by taurine administration. Thus, the agent for improving the taurine modification of mitochondrial tRNALeu(UUR) of the present invention is useful for improving or preventing a decrease in the taurine modification rate of mitochondrial tRNALeu(UUR), particularly, a decrease in the taurine modification rate of normal mitochondrial tRNALeu(UUR), associated with senescence, in, in addition to healthy subjects, non-disease subjects and subjects who are at risk of developing some disease, as well as patients having some disease, in particular, mitochondrial disease patients and subjects at risk of developing such disease.
Furthermore, the taurine modification rate of normal mitochondrial tRNALeu(UUR) is useful as a biomarker for selection of subjects of taurine therapy currently under development for mitochondrial disease patients, use for companion diagnosis to be used for determination of the treatment effect thereof and assistance therefor.
A granule of the above-mentioned formulation was prepared by a conventional method.
Purified water is added to a total amount of 180 mL.
An internal liquid of the above-mentioned formulation was prepared by a conventional method.
Purified water is added to a total amount of 50 mL.
A drink agent of the above-mentioned formulation was prepared by a conventional method.
The present inventors have found that the taurine modification rate of normal tRNALeu(UUR), among the mitochondrial tRNAs, serves as an index of senescence. The taurine modification rate of normal tRNALeu(UUR) is a universal marker capable of grasping the state of not only mitochondrial disease patients but also healthy individuals. Taurine is useful as a pharmaceutical product, quasi-drug, cosmetic or food for improving the taurine modification rate of mitochondrial tRNALeu(UUR) that decreased due to aging and an influence of, for example, lifestyle and environmental factors such as intense fatigue and the like, genetic factor and the like, and the like.
While some of the embodiments of the present invention have been described in detail in the above, those of ordinary skill in the art can make various modifications and changes to the particular embodiments shown without substantially departing from the teaching and advantages of the present invention. Such modifications and changes are encompassed in the spirit and scope of the present invention as set forth in the appended claims.
This application is based on a patent application No. 2016-062910 filed in Japan (filing date: Mar. 26, 2016), the contents of which are incorporated in full herein.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2016-062910 | Mar 2016 | JP | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/JP2017/012205 | 3/25/2017 | WO | 00 |
